News & Events Upcoming events Sep 21, 2026 - Sep 23, 2026 International Congress on Neurodegenerative Diseases - ICND 2026 Sevilla, Spain More info and meet us there Oct 21, 2026 - Oct 23, 2026 MSToronto 2026 - 10th Joint ACTRIMS-ECTRIMS Meeting Toronto, Canada More info and meet us there Nov 16, 2026 - Nov 19, 2026 MEDICA 2026 Düsseldorf, Germany More info and meet us there See all upcoming events Latest news May 30, 2011 Fujirebio Diagnostics, Inc. Receives FDA 510 (k) Clearance for First Biomarker to Monitor Lung Cancer Read more Sep 23, 2010 Fujirebio completed the acquisition of Innogenetics Read more Jul 19, 2010 Fujirebio to acquire Innogenetics from Abbott Read more May 3, 2009 BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management Read more Jan 26, 2009 Fujirebio Diagnostics and Abbott Agree to Develop New Ovarian Cancer Test for Abbott's ARCHITECT® Analyzers Read more Jan 25, 2009 Pivotal Data Published for First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass Read more Load More
Sep 21, 2026 - Sep 23, 2026 International Congress on Neurodegenerative Diseases - ICND 2026 Sevilla, Spain More info and meet us there
Oct 21, 2026 - Oct 23, 2026 MSToronto 2026 - 10th Joint ACTRIMS-ECTRIMS Meeting Toronto, Canada More info and meet us there
May 30, 2011 Fujirebio Diagnostics, Inc. Receives FDA 510 (k) Clearance for First Biomarker to Monitor Lung Cancer Read more
May 3, 2009 BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management Read more
Jan 26, 2009 Fujirebio Diagnostics and Abbott Agree to Develop New Ovarian Cancer Test for Abbott's ARCHITECT® Analyzers Read more
Jan 25, 2009 Pivotal Data Published for First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass Read more
